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Background: Idiopathic pulmonary fibrosis, the most common form of idiopathic interstitial pneumonia, is
characterized by progressive, irreversible scarring of the lung parenchyma. Idiopathic pulmonary fibrosis has a
poor prognosis, and there are no medical therapies available that have been shown to improve survival. It is
usually sporadic, but there is evidence of familial clustering of pulmonary fibrosis, suggesting a genetic basis for
this disease. More recently, studies have confirmed that specific genetic variants are associated with both familial
and sporadic forms of pulmonary fibrosis.
Discussion: Although there are common and rare genetic variants that have been associated with the risk of
developing pulmonary fibrosis, the genotyping of patients is not a generally accepted strategy. Better understanding
of the interplay between genetic risk and environmental exposure is likely needed to inform both treatment and
disease prevention. Several identified disease-associated genetic variants have implications for disease progression
and survival, but systematic studies of known genetic variants and their influence on therapeutic efficacy are lacking.
Future investigations should focus on understanding phenotypic differences between patients carrying different risk
alleles, and clinical studies should be designed to control for the influence of different genetic risk variants on patient
outcomes.
Summary: Inherited genetic factors play a significant role in the risk of developing pulmonary fibrosis. Future studies
will be needed to characterize patient phenotypes and to understand how these genetic factors will influence
clinical decision-making for both diagnosis and treatment of idiopathic pulmonary fibrosis.
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Idiopathic pulmonary fibrosis (IPF), the most common
idiopathic interstitial pneumonia (IIP), is characterized
by progressive scarring of the lung parenchyma. The
prognosis of IPF is poor, with a median survival from
time of diagnosis of 3 years [1, 2]. The precise etiology
of this disease has remained elusive despite decades of
research. It is thought that IPF results from the aberrant
behavior of injured alveolar epithelial cells, which in turn
produce growth factors that induce proliferation of
resident fibroblasts, recruitment of fibrocytes, and
epithelial-to-mesenchymal transition [3]. This is thought
to lead to the formation of interstitial fibroblastic foci* Correspondence: susan.mathai@ucdenver.edu
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the the histopathologic pattern of IPF, the accumula-
tion of extracellular matrix, and lung remodeling [3].
Recent evidence has shown that there is an inherited
risk of developing IPF, and specific genetic variants
have been identified that are strongly associated with
the disease.
Initial investigations distinguished between familial
and sporadic forms of IPF, though there is increasing
evidence that genetic risk factors play a significant role
in both forms of the disease [4–6]. Although investiga-
tors continue to uncover genetic risk factors for disease
and to probe their connections to IPF pathophysiology,
the full clinical implications of these genetic discoveries
remain unknown. Here, we briefly summarize the
current knowledge regarding genetic risk and the devel-
opment of IPF, describe how these genetic findings mayle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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and suggest avenues for further investigation into the
clinical implications of genetic risk in this disease.
Focus on familial disease: early investigation into genetic
risk and pulmonary fibrosis
Early evidence of inherited risk for the development of pul-
monary fibrosis was based on twin studies and familial ag-
gregation of cases [7–10]. Even though these early studies
suggested an inherited risk, the first specific disease associ-
ated gene variants were identified after 2000 and included
surfactant protein mutations among familial cases of pul-
monary fibrosis [11–14], specifically in the genes for surfac-
tant protein C (SFTPC) and SFTPCA [12, 14, 15]. There are
also rare familial syndromes associated with pulmonary fi-
brosis, such as Hermansky–Pudlak syndrome. This disorder
is caused by defects in intracellular protein trafficking, such
as mutations in AP3B1, which are central to this genetically
heterogeneous autosomal recessive disorder [16, 17].
Pulmonary fibrosis also occurs in dyskeratosis conge-
nita, a syndrome characterized by aplastic anemia,
myelodysplastic syndrome, skin hyperpigmentation, nail
dystrophy, and pulmonary and liver fibrosis [18, 19].
There are a number of genetic mutations associated with
dyskeratosis congenita, including mutations in dyskera-
tosis congenita 1 (DKC1), a gene involved in the
stabilization of telomeres [18], as well as in other tel-
omerase genes [19], pointing to telomeropathy as a po-
tential underlying mechanism for fibrosis. Investigations
of familial IPF cases and their kindred identified germ-
line mutations in the telomerase genes telomerase reverse
transcriptase (TERT) and telomerase RNA component
(TERC) in up to one-sixth of pulmonary fibrosis families
[19–21]. Importantly, TERT and TERC mutations were
present in cases of both familial and sporadic IPF, and indi-
viduals with these mutations had shorter telomeres when
compared to age-matched family members without muta-
tions [22]. Recent studies by Cogan and colleagues describe
rare variants in the genes encoding regulator of telomere
elongation helicase 1 (RTEL1) and polyadenylation-specific
ribonuclease deadenylation nuclease (PARN) associated
with familial disease. These rare variants were found
through exome-sequencing of familial interstitial pneumo-
nia (FIP) cases [23, 24]. Patients with these variants had
profound shortening of telomeres in peripheral blood
mononuclear cells, though the mechanism by which loss
of PARN affects telomere length is unknown. These newly
described rare variants further point to telomere length’s
being important in the pathogenesis of IPF [23, 24].
Transition of focus from familial to sporadic disease
MUC5B
The previous studies focused on understanding genetic
risk for disease conferred by rare variants by studyingfamilial clustering of pulmonary fibrosis. However, in
2011, Seibold and colleagues found that common genetic
variants were highly associated with familial as well as
sporadic pulmonary fibrosis [6]. The authors used a
genome-wide linkage analysis followed by sequencing to
determine that a single nucleotide polymorphism (SNP)
rs35705950 on the p-terminus of chromosome 11 is
strongly associated with IPF as well as with FIP. FIP in
this study was defined by the presence of two or more
cases of definite or probable IIP within three generations
of a family [6].
The common variant rs35705950 is found in the pro-
moter region of the of mucin 5B (MUC5B) gene, which
codes for a highly conserved region of the mucin pro-
moter across primate species. Heterozygous (GT) and
homozygous (TT) individuals had an odds ratio for de-
veloping disease of 6.8 and 20.8 for FIP, and 9.0 and 21.8
for IPF, respectively, demonstrating the strength of the
SNP's association with disease development. Further-
more, an IPF diagnosis was associated with a more than
14-fold increase in MUC5B expression in the lung regard-
less of genotype, but the presence of the minor allele (T) at
rs35705950 was associated with a 37.4-fold increase in
gene expression even in unaffected individuals. MUC5B
has also been found in honeycomb cysts, one of the hall-
mark pathologic findings of IPF [25].
This discovery was further validated in seven inde-
pendent non-Hispanic white cohorts [4, 26–31], and the
MUC5B promoter polymorphism remains the strongest
and most replicated genetic risk factor for pulmonary
fibrosis. In the initial study describing the association be-
tween rs35705950 and IPF, the minor allele frequency
was 33.8 % in familial cases, 37.5 % in sporadic IPF
cases, and 9.1 % in control subjects [6]. This highlights
two important points: (1) the frequency of the risk allele
is the same in familial and sporadic cases of IPF and
(2) the frequency of the risk allele in the general
non-Hispanic white control group implies interplay
between genetic risk and environmental exposure in
the development of IPF.
The importance of the rs35705950 variant in the
pathogenesis of lung fibrosis was further illustrated by a
recent study that examined the Framingham Heart
Study population and found that the rs35705950 minor
allele frequency was 10.5 %. After adjusting for covari-
ates, the odds of radiographic interstitial lung abnormalities
were 2.8 times greater for each copy of the rs35705950
minor allele. This study for the first time demonstrated a
link between this polymorphism and radiographic intersti-
tial lung abnormalities that could be considered “pre-fi-
brotic,” and also suggested that the rates of definite
radiographic evidence of pulmonary fibrosis in individuals
over 50 years of age may be 2 %, higher than what had been
reported previously in the literature [1, 32]. These results
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notion that genetic information may be able to guide inter-
ventions to detect early fibrosis or pre-fibrotic lung lesions
in asymptomatic individuals, suggesting a potential role for
disease prevention, in addition to treatment, in the manage-
ment of IPF [32].
The association of the MUC5B promoter polymorph-
ism appears to be specific to pulmonary fibrosis. Cohorts
with systemic sclerosis and interstitial lung disease
[29, 33], asbestosis, sarcoidosis [27], acute lung injury
or acute respiratory distress syndrome, chronic obstructive
pulmonary disease, and asthma have failed to show strong
associations between disease and genotype for this variant
[34]. In addition, rs35705950 was a strong genetic risk
factor for IPF in a Mexican population (odds ratio = 7.36,
P = 0.0001), but was rare in Korean cases of IPF and was
absent in Korean healthy controls [35]. Other studies
found that the SNP had slightly higher prevalence among
Japanese IPF cases (3.4 %) compared to healthy controls
(0.8 %), and among Chinese IPF cases (3.3 %) compared to
controls (0.7 %) [31, 36]. The prevalence of the MUC5B
promoter SNP across different populations reflects disease
prevalence in different racial or ethnic backgrounds:
Caucasians appear to be at a higher risk of developing IPF
than Hispanics and Asians while this disease is rare in
populations of African descent [37]. Interestingly, the
MUC5B polymorphism is not present in African popula-
tions [38]. Therefore, rs35705950 is likely to be important
in some groups beyond the non-Hispanic white popula-
tion for the development of IPF.
Other common variants and IPF
Genome-wide association studies (GWAS) have been
performed in patients with one of the fibrotic IIPs (of
which IPF is the most common) to identify additional
variants that confer risk of disease. In 2013, Fingerlin
and colleagues published a case–control GWAS in 1616
non-Hispanic white IIP patients and 4683 controls. This
was supported by a replication study of 876 cases and
1890 controls [4]. This study confirmed the association
between TERT at chromosome 5p15, MUC5B at 11p15,
and the 3q26 region near TERC, but also identified
seven new loci associated with disease, including
FAM13A (4q22), DSP (6p24), OBFC1 (10q24), ATP11A
(13q34), DPP9 (19p13), and chromosomal regions 7q22
and 15q14-15 [4]. These common variants associated
with fibrotic IIP suggest that host defense (MUC5B,
ATP11A), cell–cell adhesion (DSP and DPP9), and DNA
repair (TERT, TERC, and OBFC1) may be important in
disease pathogenesis [4, 34, 39]. These genetic loci, ex-
cluding rs35705950, account for approximately one-
third of disease risk, emphasizing the importance of
inherited genetic risk in disease pathogenesis [4, 34].
Furthermore, similar to the rs35705950 observationsmade by Seibold and colleagues, there were no substan-
tial differences in odds ratios for disease between pa-
tients with familial and sporadic IPF, or between
different forms of non-IPF IIP, suggesting that (1) the
genetic risk factors for fibrotic IIPs are similar and that
(2) familial and sporadic cases of IPF have similar gen-
etic backgrounds.
A second GWAS performed in patients with IPF
confirmed the association of the MUC5B promoter vari-
ant with IPF and also identified additional variants in
Toll-interacting protein (TOLLIP) and signal peptide
peptidase-like 2C (SPPL2C) as potential risk loci [28].
Discussion: clinical implications of genetic
discoveries in pulmonary fibrosis
Phenotypic differences in carriers of the rare telomerase
mutations
Identification of the constellation of findings (liver ab-
normalities, cytopenias, premature graying of the hair)
consistent with rare genetic mutations in TERT or TERC
mutations is critical, as these patients are at risk for
bone marrow failure and cryptogenic liver cirrhosis [40].
Evidence suggests that in autosomal dominant forms of
FIP caused by coding mutations in TERT, a unique form
of genetic anticipation causes a shift from a pulmonary
fibrosis predominant phenotype to one characterized by
bone-marrow failure over successive generations [21].
Patients carrying TERT mutations have a poor prognosis
with reduced life expectancy [41].
One of the few therapeutic options for patients with
pulmonary fibrosis is lung transplantation. In the case of
patients with TERT mutations, a small observational study
suggests that complications of lung transplantation, such
as renal failure, may be more common in IPF patients
with telomerase mutations and/or shortened telomere
syndrome [42], suggesting that genotyping could be im-
portant in determining transplant eligibility. This is par-
ticularly relevant in post-transplant patients who require
significant immunosuppression because patients with
these telomerase mutations experience increased rates of
bone marrow suppression and medication-related compli-
cations [42], which may reflect their underlying dimin-
ished their underlying diminished bone marrow reserves.
The authors caution that this observation has yet to be
confirmed in larger cohorts of patients but suggest that
careful consideration of the patients’ hematologic and
hepatic status is warranted pre-transplantation [42].
Survival differences based on genetic risk
Three observational studies have illustrated that com-
mon genetic variants associated with disease are also as-
sociated with differences in survival. In 2013, Noth and
colleagues reported that several variants in TOLLIP were
associated with IPF; however, carriers of the minor allele
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but those with IPF who had this allele experienced in-
creased mortality [28]. Another study published the
same year described a survival advantage for individuals
with the minor allele at rs35705950, the MUC5B pro-
moter polymorphism strongly associated with disease
[33]. Another functional SNP found in Toll-like receptor
3 (TLR3) has been associated with increased mortality
and with accelerated disease progression in patients with
IPF [43]. The mechanism for these observed differences
in mortality remains unknown, but could be related to
underlying differences in disease pathogenesis or in the
clinical response to commonly prescribed therapies.
As numerous investigators have shown, various gen-
etic variants, both rare and common, in telomere-related
genes are associated with disease status [20, 23, 24].
Telomere length itself is also associated with transplant-
free survival time for patients with IPF independent of
age, sex, forced vital capacity, or diffusing capacity of
carbon monoxide [44]. Additional studies are necessary
to establish what the clinically relevant telomere length
thresholds might be and how this measurement could
function as an IPF biomarker or affect choice of therapy.
Genotypes in the clinic and in clinical trials
We suggest that further studies will continue to eluci-
date phenotypic differences between patients with IPF
who have different disease-associated genetic variants.
The clinical significance of these specific genetic variants
remains unknown. Though strongly statistically associated
with disease, the effect size of most common variants isFig. 1 The genetic basis of idiopathic pulmonary fibrosis. This figure represe
pulmonary fibrosis and their relative allele frequency and effect size. Though
whereas common variants, though strongly statistically associated with dise
rs35705950, though common, has a significant effect size. The low effect siz
interaction in the overall risk of disease. (Adapted and reproduced with permsmall, whereas the effect size of rare variants is large
(Fig. 1). The relationship between different common vari-
ants and their potential interaction with rare variants in
disease pathogenesis will be an area of future investigation.
Because the clinical significance of these more com-
mon genotypes remains unknown, routine genotyping of
individuals with IPF is not recommended. Furthermore,
no evidence exists to suggest that genetic data should
determine the selection of approved therapies for IPF,
such as pirfenidone [45], nintedanib [46], or lung trans-
plantation [47], for any individual patient. At this time,
the specific treatment options for any given patient
should be made on the basis of the published known
risks and benefits of the medications, all of which have
been studied independently of genotype [45, 46].
However, future investigations and clinical trials will
need to take into account potential genotypic variation
between different genotypes, especially as they likely
affect the primary outcomes for clinical trials [48, 49].
Failure to control for genotypes, such as the MUC5B
promoter polymorphism, would be tantamount to failing
to control for other factors such as age, sex, and baseline
lung function that are known to influence clinical out-
comes. Post-hoc analysis of existing clinical trial data
stratifying groups by the presence of common risk alleles
might also generate intriguing hypotheses to be validated
in prospective studies.
Risk for family members
Given the unpredictable clinical course of IPF, its poor
prognosis, and lack of available mortality-modifyingnts the spectrum of genetic variants known to confer risk for idiopathic
rare variants have a low allele frequency, their effect size is profound,
ase, have a low effect size. The MUC5B promoter polymorphism
e of the common variants could suggest a strong gene-by-environment
ission from Antonarakis et al., Nature Rev Genetics 2010, 11:380.) [53]
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with early disease. Given the low prevalence of IPF, it is
not a disease for which physicians routinely screen
asymptomatic patients. However, the growing evidence
for inherited disease risk may prompt the pulmonary
community to reconsider the need to seek out patients
for early diagnosis among at-risk populations.
In the case of FIP, it is known that first-degree relatives
of patients with pulmonary fibrosis are at high risk of
developing lung abnormalities, but the clinical signifi-
cance of these abnormalities are unclear [8]. In 1986,
Bitterman and colleagues studied family members of
patients with autosomal-dominant FIP. They found that
first-degree family members without clinically apparent
disease had bronchoalveolar lavage fluid with increased
inflammatory cells, but whether these individuals deve-
loped pulmonary fibrosis was not studied [8]. Twenty-
seven years later, follow-up evaluation of two of these
patients revealed interim development of radiographic
evidence of pulmonary fibrosis, as well as symptomatic
and measurable respiratory impairment [50]. Though
this study was limited by its small sample size, it illus-
trates that alveolar inflammation in first-degree relatives
of FIP patients can progress to overt pulmonary fibrosis
and that these patients can experience a long duration of
preclinical disease. More recently, extensive phenotyping
of first-degree relatives of patients with FIP revealed evi-
dence of dysfunction in pathways associated with the de-
velopment of pulmonary fibrosis, including telomere
shortening, endoplasmic reticulum stress, and elevated
MUC5B levels [51]. These findings were observed in rela-
tives with and without evidence of disease by high-
resolution computed tomography or transbronchial lung
biopsy, suggesting that these at-risk individuals have mo-
lecular abnormalities that precede symptoms or clinical de-
tection. More than one-third of the at-risk subjects had
histologically abnormal lung tissue, and 14.7 % had evi-
dence of early interstitial lung disease [51]. Further obser-
vation will be required to determine the significance of
these findings and of the results of the Framingham Heart
study [32] with respect to identifying which asymptomatic
subjects will progress to pulmonary fibrosis and whether
early intervention prevents clinical worsening.
Although numerous studies have now shown that asymp-
tomatic individuals who are at risk based on pedigree or
who carry known risk alleles like the rs35705950 variant
have higher rates of interstitial lung abnormalities [32, 51],
there is no data to suggest that intervention is indicated. In
part, this is due to the lack of data concerning the natural
history of asymptomatic interstitial lung abnormalities.
However, family members of patients with FIP should re-
main vigilant for the development for respiratory symptoms
and should refrain from exposure to known environmental
pulmonary toxins such as tobacco smoke [52].Summary
There is growing evidence that IPF is a disease in which
genetic risk plays a central role. There are both common
and rare variants that are associated with increased dis-
ease risk, and future studies will need to clarify the rela-
tionship between these variants and environmental
exposures in the initiation and progression of IPF. The
consideration of genetic risk factors in IPF will allow us to
better phenotype the disease, because observational stud-
ies have shown that genotypes significantly affect clinical
outcomes. A better understanding of genetic risk and its
role in disease diagnosis will lead to detection of early
asymptomatic cases and will allow us to personalize thera-
peutic choices based on inherited risk.
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